Latest oncology clinical development updates

Tuesday, March 11, 2025

Subscribe here

Read this newsletter online

OTW News Highlights this week

- Molecular Partners - Novartis collaboration to develop DARPin-conjugated radioligands for cancer comes to an end
- Jazz Pharmaceuticals to Acquire Chimerix
- VERSATILE-003 Ph 3 Trial of Versamune HPV in HPV16-Positive Head and Neck Cancer Initiated
- Ph 3 Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab published in The Lancet
- Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) ALL
- Sun Pharma to Acquire Checkpoint Therapeutics
- Patient Enrollment completed in Ph 3 Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent HCC
- ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial
- FDA Clears IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL

- TEVIMBRA Approved in U.S. for 1L Treatment of Advanced ESCC in Combination with Chemotherapy

European Commission Approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with Unresectable or Advanced HCC

"The European Commission's approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "This approval marks a critical milestone in our commitment ...

Read more Drug Approvals

FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

"Receiving FDA's orphan drug designation for bexmarilimab for the treatment of myelodysplastic syndrome marks a significant milestone for Faron Pharmaceuticals as we

continue to develop bexmarilimab for MDS and other cancers. This FDA ODD along with the previously granted FDA fast track designation highlights our continued progress and reinforces our belief in the potential of bexmarilimab to address this significant ...

FDA's IND Approval of LAE120 for Treatment of Advanced Solid Tumors Announced

"Leveraging our deep know-how and extensive expertise in drug discovery, Laekna has developed a distinctive portfolio of innovative drug candidates through the close collaboration of our Med Chem, Biology and AIDD (AI-driven Drug Discovery) teams, continuously advancing preclinical drug candidates into clinical stage. Laekna has also significantly accelerated the progress of drug discovery by utilizing cutting-edge artificial intelligence tools", said ...

Read more Regulatory News

Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced

Christina Coughlin, CEO of Avacta Therapeutics commented, "We are very pleased to advance to the expansion cohorts in the AVA6000 trial in these three indications with high unmet need. Our development of AVA6000 is proceeding according to plans and today's new data demonstrate the durability of the responses we have observed in the SGC indication. We believe that AVA6000 has ...

Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said: “MATTERHORN is the first Phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction cancers. This perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel therapies can have ...

Read more Trial Results

Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations

“We are very optimistic about the prospects of our investigational drug Multikine in 2025 and 2026. We look ahead to Multikine being able to deliver much needed relief to a patient population with a severe unmet medical need. We see several very important milestones and value drivers upcoming. Positive data on presurgical response rates, previously shown to be indicative of ...

First Patient Dosed in Ph 1 Study of ALTA3263 in Advanced Solid Tumors

“With this trial, we hope to bring a breakthrough therapy to the many patients with KRAS-driven cancers who are still underserved,” said Andrew Chi, M.D., Ph.D., Chief Medical

Officer of Alterome. “We have shown in preclinical studies that ALTA3263 has the attributes to potentially address this significant unmet need and transform patient outcomes.”

Read more Trial Status

Zymeworks Announces Achievement of $14M Milestone from GSK Collaboration

“In April 2016, we entered into a platform technology transfer and license agreement with GSK to research, develop and commercialize up to six bispecific antibodies generated using our Azymetric™ platform. Under the terms of this agreement, we granted GSK a worldwide, royalty-bearing antibody sequence pair-specific exclusive license to research, develop and commercialize licensed products. In May 2019, this agreement was ...

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen

“This second DC nomination is a testament to our strong collaboration with Ipsen and once again underscores the dedication and ingenuity of Marengo’s research team in advancing innovative immunotherapy candidates to clinical trials,” said Andrew Bayliffe Ph.D., Chief Scientific Officer of Marengo. “Our novel, first in class TCRVβ-targeted dual T cell agonists drive the revitalization of anti-tumor T cell responses ...

Read more Business News

Editor's Desk

Editor's Desk

Author

- Richa Tewari, PhD

Managing Editors

- Shalini Roy Choudhury, PhD
- Anusha Jayaraman, PhD

Social Media Managers

- Siftjit Kaur, PhD
- Himanshi Agarwal, PhD